NEW YORK (GenomeWeb News) – PamGene International announced today that it has entered into a co-marketing pact with Invitrogen covering nuclear hormone receptor products.
Under the alliance, the firms will co-market Invitrogen’s nuclear hormone receptor proteins and Lanthascreen assay technology with PamGene’s microarray-based nuclear hormone receptor screening tools including its PamChip applications and PamStation instruments.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

University of California, San Diego, researchers have developed a gene drive to control a fruit-destroying fly.

A new study of a β-thalassemia gene therapy appears promising, according to NPR.

In Nature this week: hair color genes, hybridization between 13-year and 17-year cicadas, and more.

Futurism writes that gene doping could be the next generation of cheating in sports.